Kymera Therapeutics (KYMR) Projected to Release Earnings on Thursday

Kymera Therapeutics (NASDAQ:KYMR) is projected to announce its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect the company to announce earnings of ($1.27) per share and revenue of $3.10 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:30 AM ET.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Wednesday, August 5th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.09. The firm had revenue of $65.00 million during the quarter, compared to the consensus estimate of $32.78 million. During the same quarter in the prior year, the business posted ($0.95) earnings per share. Kymera Therapeutics’s revenue for the quarter was up 465.2% compared to the same quarter last year. On average, analysts expect Kymera Therapeutics to post ($3.85) EPS for the current fiscal year and ($5.09) EPS for the next fiscal year.

Kymera Therapeutics Price Performance

Shares of KYMR stock opened at $117.57 on Wednesday. The business’s 50-day moving average price is $114.90 and its 200-day moving average price is $95.60. Kymera Therapeutics has a 12 month low of $55.66 and a 12 month high of $130.05.

Wall Street Analysts Forecast Growth

KYMR has been the topic of several recent research reports. Bank of America lifted their target price on shares of Kymera Therapeutics from $123.00 to $144.00 and gave the stock a “buy” rating in a research report on Monday, September 14th. Guggenheim upped their price target on shares of Kymera Therapeutics from $135.00 to $170.00 and gave the company a “buy” rating in a research report on Monday, August 31st. Raymond James Financial initiated coverage on shares of Kymera Therapeutics in a research report on Thursday, October 8th. They issued an “outperform” rating and a $140.00 price target for the company. Barclays raised their price target on shares of Kymera Therapeutics from $133.00 to $139.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Finally, TD Cowen upgraded shares of Kymera Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $135.12.

Insider Activity

In other Kymera Therapeutics news, CEO Nello Mainolfi sold 30,000 shares of the company’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $113.80, for a total transaction of $3,414,000.00. Following the sale, the chief executive officer owned 666,568 shares of the company’s stock, valued at approximately $75,855,438.40. This represents a 4.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Brian Adams sold 6,371 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $116.83, for a total value of $744,323.93. Following the sale, the insider directly owned 50,254 shares of the company’s stock, valued at $5,871,174.82. This represents a 11.25% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 15.98% of the company’s stock.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins through targeted protein degradation. Its approach is designed to use the cell’s natural protein-disposal system to remove proteins that may be difficult to address with conventional drug modalities.

The company’s research and development programs have targeted a range of disease areas, including immune-mediated and inflammatory conditions, cancer, and other serious illnesses.